Results 111 to 120 of about 61,152 (267)

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review

Anaesthesiology Intensive Therapy
An increasing number of patients treated with novel antidiabetic drugs, including glucagon-like-peptide-1 receptor agonists (GLP-1RA), dual glucose-dependent insulinotropic polypeptide receptor agonists and sodium-glucose cotransporter-2 (SGLT2 ...
Oliwia Doroba, Leszek Czupryniak, Filippo Sanfilippo, Paweł Andruszkiewicz, Mateusz Zawadka   +4 more
doaj   +1 more source

Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aims to examine weight‐loss history and pre‐treatment concerns, and their associations with current functioning and well‐being in adults undergoing incretin‐based pharmacotherapy for obesity. Materials and Methods This cross‐sectional study analysed 411 adults treated with three different incretin‐based medications. Demographics,
Ali Kapan, Tobias Brandl, Thomas Waldhör, Othmar Moser, Richard Felsinger   +4 more
wiley   +1 more source

Diffractive production of dijets by double Pomeron exchange processes

, 2003
A phenomenological description of diffractive dijet hadroproduction via double Pomeron exchange is presented. This description is based on a modified version of the Ingelman-Schlein model which includes the evolution of the Pomeron structure function and
A. A. Natale, A. Berera, A. Berera, A. D. Martin, A. Donnachie, A. H. Mueller, D. Graudenz, E. Gotsman, G. Altarelli, G. Ingelman, H. Jung, J. Collins, J. Pumplin, K. Goulianos, K. Goulianos, M. Boonekamp, M. Gluck, M. S. Soares, N. I. Kochelev, R. J. M. Covolan, R. J. M. Covolan, R. J. M. Covolan, R. J. M. Covolan, T. Affolder, V. A. Khoze, V. A. Khoze, V. M. Abazov, V. N. Gribov, V. N. Gribov, Yu. L. Dokshitzer   +29 more
core   +1 more source

Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims/Hypothesis Initial dose‐escalation has been shown to mitigate gastrointestinal adverse events in people treated with incretin‐based medications. We aimed to analyse dose‐response relationships for the proportion of study participants reporting nausea and vomiting among those exposed to incretin mimetics approved for Type 2 diabetes (GLP‐1
Michael A. Nauck, Viktoria Punov, Yu Mi Kang, Soo Lim   +3 more
wiley   +1 more source

Testing gravity on large scales. The skewness of the galaxy distribution at z~1

, 2008
We study the evolution of the low-order moments of the galaxy overdensity distribution over the redshift interval 0 ...
Abbas, U., Adami, C., Arnouts, S., Bardelli, S., Bolzonella, M., Bondi, M., Bongiorno, A., Bottini, D., Brinchmann, J., Brun, V. Le, Buzzi, A., Cappi, A., Charlot, S., Ciliegi, P., Contini, T., Cucciati, O., de la Torre, S., de Ravel, L., Fevre, O. Le, Foucaud, S., Franzetti, P., Garilli, B., Gavignaud, I., Gregorini, L., Guzzo, L., Ilbert, O., Iovino, A., Lamareille, F., Maccagni, D., Marano, B., Marinoni, C., Mathez, G., Mazure, A., McCracken, H. J., Mellier, Y., Meneux, B., Merighi, R., Merluzzi, P., Paltani, S., Pellò, R., Perez-Montero, E., Picat, J. P., Pollo, A., Pozzetti, L., Radovich, M., Scaramella, R., Scodeggio, M., Taxil, P., Temporin, S., Tresse, L., Vergani, D., Vettolani, G., Virey, J. M., Walcher, C. J., Zamorani, G., Zanichelli, A., Zucca, E.   +56 more
core   +1 more source

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction‐Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity‐management modalities exert weight‐independent hepatic effects remains uncertain.
Matteo Monami, Amanda Belluzzi, Silvio Buscemi, Luca Busetto, Ricardo Cohen, Maurizio De Luca, Andrea Galli, Edoardo Mannucci, Tarissa Z. Petry, Benedetta Ragghianti, Paolo Sbraccia, Dror Dicker   +11 more
wiley   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) arises from dysregulated interactions between nutrient delivery, adipose tissue lipid handling and liver lipid metabolism, which collectively coalesce to drive inflammatory signalling leading to metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis. Recent clinical
Evangelia E. Tsakiridis, Gregory R. Steinberg   +1 more
wiley   +1 more source

Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo‐Controlled, Double‐Blind, Crossover Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Oxytocin is expressed throughout the small intestine, suggesting a role for oxytocin in postprandial metabolism. Accordingly, single‐dose intranasal oxytocin reduces food intake and improves glucose tolerance. We investigated the effects of a continuous intravenous oxytocin infusion on ad libitum food intake, appetite sensations ...
Ida M. Gether, Vivian Kliim‐Hansen, Petur T. Olafsson, Miriam G. Pedersen, Casper K. Nielsen, Anne‐Marie Ellegaard, Mikkel B. Christensen, Jens F. Rehfeld, Jørn W. Helge, Jens J. Holst, Bolette Hartmann, Filip K. Knop, Lærke S. Gasbjerg, Asger B. Lund   +13 more
wiley   +1 more source